ALTER — Theradiag SA Share News
0.000.00%
Last trade - 00:00- €16.44m
- €12.36m
- €12.20m
Brief: Theradiag FY revenue rises 6% to 7.6 million euros
Brief: Theradiag says new CE marking obtained for its Entyvio test
Brief: Theradiag announces results of the ROC trial
Brief: Theradiag renews standby equity facility with Societe Generale
Brief: Theradiag announces strategic agreement with Miraca Life Sciences in the USA
Brief: Theradiag and HOB Biotech sign stratetic partnership in Asia and Europe
Brief: Theradiag H1 net loss widens to 2.0 mln euros
Brief: Theradiag signs new collaboration agreements
Brief: 250,000 new Theradiag shares to be listed - Euronext
Brief: Theradiag and Hospira sign a partnership agreement
Brief: Theradiag launches Lisa Tracker in Canada
Brief: Theradiag says study including infliximab published in Journal of Crohn's and Colitis
Brief: Theradiag receives CE marking for its 10th biotherapy monitoring test
Brief: Theradiag receives CE marking for its Herceptin monitoring
Brief: Theradiag FY net loss widens to 2,964,000 euros
Brief: Theradiag enters into master services agreement with UCB
Brief: Theradiag FY revenue rises to 7.1 million euros
Brief: Theradiag H1 net loss rises to 1.4 million euros